Clearance of Driver Mutations after Transplantation for Myelofibrosis by Nico Gagelmann et al.
Eddie Cliff, Haematology Registrar at Peter MacCallum Cancer Centre, shared a post on X about a recent paper by Nico Gagelmann, Co-founder and Co-chair of the European Society for Blood and Marrow Transplantation (EBMT) Trainee Committee, published in NEJM:
“Huge congrats to my friend Nico Gagelmann and colleagues for their work just out in NEJM!
They show that patients with MF whose driver mutations are cleared with allograft do better long term, especially those with early clearance.”
“Clearance of Driver Mutations after Transplantation for Myelofibrosis”
Authors: Nico Gagelmann, Marie Quarder, Anita Badbaran, Francis Ayuk, Nicolaus Kröger et al.
Nico Gagelmann is a physician and scientist who co-founded and co-chairs the European Society for Blood and Marrow Transplantation (EBMT) Trainee Committee, and he also serves as the chair of the EBMT subcommittee focused on CAR-T cell therapies for plasma cell disorders.
His work is particularly impactful in the realm of CAR-T treatments for multiple myeloma, where he has contributed to advancing research and clinical approaches.
More posts featuring Nico Gagelmann and Eddie Cliff.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023